tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Dermatitis D003872 30 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pharyngitis D010612 2 associated lipids
Shock D012769 11 associated lipids
Erythema D004890 22 associated lipids
Dermatomycoses D003881 17 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cholelithiasis D002769 16 associated lipids
Fever D005334 35 associated lipids
Amenorrhea D000568 4 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Shock, Septic D012772 11 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Cough D003371 19 associated lipids
Paraproteinemias D010265 2 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Ovarian Cysts D010048 4 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Renal D006977 9 associated lipids
Metaplasia D008679 7 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Tachycardia D013610 7 associated lipids
Cicatrix D002921 9 associated lipids
Neutropenia D009503 15 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Urticaria D014581 13 associated lipids
Behcet Syndrome D001528 7 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Thrombophlebitis D013924 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
HIV Seropositivity D006679 15 associated lipids
Uveitis D014605 14 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Villalba L and Adams EM Update on therapy for refractory dermatomyositis and polymyositis. 1996 Curr Opin Rheumatol pmid:9018458
Sano Y et al. Effect of a single injection of high-dose FK506 on lung transplantation in rats. 1996 Surg. Today pmid:9017963
Richardson D et al. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. 1996 Nephrol. Dial. Transplant. pmid:9017633
Ishizuka T et al. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. 1997 Biochem. Biophys. Res. Commun. pmid:9016789
Noguchi N et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. 1997 J. Biol. Chem. pmid:9013543
DeCenzo MT et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. 1996 Protein Eng. pmid:9005438
Matsui A et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. 1996 Acta Paediatr Jpn pmid:9002314
Becker G et al. Rescue therapy with tacrolimus in simultaneous pancreas/kidney transplantation. 1997 Transpl. Int. pmid:9002152
Felldin M et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients--a Scandinavian multicenter analysis. 1997 Transpl. Int. pmid:9002146
Pirenne J et al. Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. 1997 Surgery pmid:9001555
Nair SC et al. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. 1997 Mol. Cell. Biol. pmid:9001212
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Rambusch EG and Manns MP [Therapy of autoimmune hepatitis]. 1996 Dtsch. Med. Wochenschr. pmid:8998922
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
pmid:8986461
Yoshikai Y et al. Clonal expansion of superantigen-reactive T cells is resistant to FK506 in mice with AIDS. 1997 J. Virol. pmid:8985410
High KP and Washburn RG Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). 1997 J. Infect. Dis. pmid:8985226
Sempuku T et al. Osteogenic potential of allogeneic rat marrow cells in porous hydroxyapatite ceramics: a histological study. 1996 J. Orthop. Res. pmid:8982133
Redmon JB et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. 1996 J. Clin. Invest. pmid:8981925
Nichterlein T et al. Effects of FK-506 on the course of murine salmonellosis. 1996 J Chemother pmid:8981186
Odom A et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. 1997 Antimicrob. Agents Chemother. pmid:8980772
Blecher O et al. A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. 1996 Plant Mol. Biol. pmid:8980498
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Morris RE Transplantation. Beware: shifting paradigms ahead. 1996 Dec 21-28 Lancet pmid:8973504
Corey HE et al. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. 1996 Pediatr. Nephrol. pmid:8971888
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Hedayat S et al. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. 1996 J Biopharm Stat pmid:8969977
Sharkey J et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. 1996 Stroke pmid:8969794
Guérette B et al. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. 1996 Muscle Nerve pmid:8965835
Teraoka S et al. [Present status and problems in clinical application of tacrolimus(FK506)]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963787
Kawasaki M et al. [Immunosuppression and the problems in partial liver transplantation]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963785
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Schumacher G et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. 1996 Transplant. Proc. pmid:8962200
Golbaekdal K et al. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. 1996 J. Pharm. Pharmacol. pmid:8961168
Antoniou E et al. Effect of RS61443 in combination with leflunomide or FK506 on rat heart allograft survival. 1996 Transpl. Int. pmid:8959858
Fändrich F et al. Circumvention of natural killer cell and T-cell mediated allogeneic target killing with tacrolimus (FK506) in small bowel transplantation related graft-vs-host disease. 1996 Transpl. Int. pmid:8959843
Gruessner RW et al. Use of FK 506 in pancreas transplantation. 1996 Transpl. Int. pmid:8959841
Jonas S et al. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. 1996 Transpl. Int. pmid:8959817
Williams R et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. 1996 Transpl. Int. pmid:8959812
Chambraud B et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. 1996 J. Biol. Chem. pmid:8955134
Ueda S et al. In-vitro metabolic studies of tacrolimus using precision-cut rat and human liver slices. 1996 J Pharm Biomed Anal pmid:8951695
Benelli U et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. 1996 J Ocul Pharmacol Ther pmid:8951679
Iwata M et al. Regulation of T cell apoptosis via T cell receptors and steroid receptors. 1996 Stem Cells pmid:8948021
Brunet M et al. Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IMX methods. 1996 Ther Drug Monit pmid:8946669
MacFarlane G et al. A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. 1996 Ther Drug Monit pmid:8946668
Winkler M et al. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. 1996 Ther Drug Monit pmid:8946659
McCall E et al. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. 1996 Circ. Res. pmid:8943949
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. 1996 Blood pmid:8943876
Adachi M et al. Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. 1996 Blood pmid:8943845
Rokaw MD et al. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells. 1996 J. Biol. Chem. pmid:8943313
Poon M et al. Rapamycin inhibits vascular smooth muscle cell migration. 1996 J. Clin. Invest. pmid:8941644
Freiberg RA et al. Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. 1996 J. Biol. Chem. pmid:8940187
Cai W et al. Transcription-modulating drugs: mechanism and selectivity. 1996 Curr. Opin. Biotechnol. pmid:8939643
Ide T et al. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the mongolian gerbil. 1996 Neurosci. Lett. pmid:8938254
Budde K et al. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. 1996 Int J Clin Pharmacol Ther pmid:8937932
Andrews PA et al. Racial variation in dosage requirements of tacrolimus. 1996 Lancet pmid:8937292
Soin AS and Jamieson NV Lessons learnt from the multicentre randomized trials of tacrolimus in liver transplantation. 1996 Sep-Oct Natl Med J India pmid:8937063
Galat A A large-scale processing of kinetic data files with derivation of the inhibitory constant Ki: an application to proline isomerases. 1996 Comput. Chem. pmid:8936426
Bader A et al. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8935714
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Shuker SB et al. Discovering high-affinity ligands for proteins: SAR by NMR. 1996 Science pmid:8929414
Yamamoto S et al. Cross-species transplantation of photoreceptors with tacrolimus hydrate (FK506) treatment. 1995 Jpn. J. Ophthalmol. pmid:8926639
Cumming DV et al. Pharmacological preconditioning of primary rat cardiac myocytes by FK506. 1996 Sep-Oct Basic Res. Cardiol. pmid:8922254
Licitra EJ and Liu JO A three-hybrid system for detecting small ligand-protein receptor interactions. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8917502
Wang X et al. Rapamycin inhibits aldolase A expression during human lymphocyte activation. 1996 J. Cell. Biochem. pmid:8913875
Yagita Y et al. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. 1996 Life Sci. pmid:8913329
Weigao C [Limb allograft in rats: studies on optimal maintenance dose of FK506 and development of graft-versus-host-disease (GVHD)]. 1996 Fukuoka Igaku Zasshi pmid:8913057
Bell A et al. The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. 1996 Gen. Pharmacol. pmid:8909976
Rozen TD et al. Treatment-refractory cyclosporine-associated headache: relief with conversion to FK-506. 1996 Neurology pmid:8909459
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Alessiani M et al. Intestinal transplantation with and without the colon in FK 506 immunosuppressed pigs. 1996 Transplant. Proc. pmid:8908021
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957